<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2400">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663531</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-180515</org_study_id>
    <nct_id>NCT02663531</nct_id>
  </id_info>
  <brief_title>Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease</brief_title>
  <official_title>Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer´s disease (AD) in one of the most important causes of dementia and poses a&#xD;
      considerable challenge in health care. Today, criteria for the diagnosis and the follow up of&#xD;
      patients with AD mainly rely either on subjective tests or invasive methods. This limits the&#xD;
      general applicability of the latter test for population screening and underlines the need for&#xD;
      the identification of easily accessible tools for the identification of high-risk subjects.&#xD;
      Because of its unique optical properties, the eye offers the possibility of the non-invasive&#xD;
      assessment of both structural and functional alterations in neuronal tissue. As the&#xD;
      neuro-retina is part of the brain, it does not come as a surprise that neuro-degenerative&#xD;
      changes in the brain are accompanied by structural and possibly also functional changes in&#xD;
      the neuro-retina and the ocular vasculature. The current study seeks to test the hypothesis&#xD;
      that beside the known anatomical changes, also functional changes can be detected in the&#xD;
      retina of patients with AD. For this purpose, flicker light induced hyperemia will be&#xD;
      measured in the retina as a functional test to assess the coupling between neural activity&#xD;
      and blood flow. Further, structural parameters such as retinal nerve fiber layer thickness&#xD;
      and function parameters such as ocular blood flow and retinal oxygenation will be assessed&#xD;
      and compared to age and sex matched controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2016</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flicker induced increase in retinal blood flow</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with mild cognitive impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Alzheimer Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DVA</intervention_name>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
    <other_name>Dynamic Vessel Analyzer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FDOCT</intervention_name>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
    <other_name>Fourier Domain Color Doppler Optical Coherence Tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pattern ERG</intervention_name>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <arm_group_label>Alzheimer Disease</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for healthy subjects&#xD;
&#xD;
          -  Men and women aged over 50 years&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  Normal findings in the medical history unless the investigator considers an&#xD;
             abnormality to be clinically irrelevant&#xD;
&#xD;
          -  Normal ophthalmic findings, ametropia &lt; 6 Dpt&#xD;
&#xD;
        Inclusion criteria for patients with AD:&#xD;
&#xD;
          -  Men and women aged over 50 years&#xD;
&#xD;
          -  Normal ophthalmic findings, ametropia &lt; 6 Dpt.&#xD;
&#xD;
          -  Confirmed diagnosis of probable AD of mild to moderate degree defined as:&#xD;
&#xD;
               1. Diagnosis of probable Alzheimer's disease based on the NINCDS/ADRDA criteria&#xD;
&#xD;
               2. Assessing the severity of Alzheimer's disease of mild to moderate degree by the&#xD;
                  Mini Mental State Examination (MMSE). AD of mild to moderate degree has been&#xD;
                  confirmed if the MMSE score is in the range of 20 to 26 inclusive&#xD;
&#xD;
          -  Hachinski Ischemia Scale is used to try and distinguish AD from multi-infarct&#xD;
             dementia. A score of ≤ 4 suggests AD Informed consent capability&#xD;
&#xD;
          -  Adequate visual and auditory acuity to allow neuropsychological testing and&#xD;
             participation in the ocular blood flow measurements&#xD;
&#xD;
          -  A potential participant has to be on stable doses of all medications he/she is taking&#xD;
             because of consisting illnesses according to medical history (except AD therapy itself&#xD;
             which will be recorded separately) for at least 30 days prior inclusion, if considered&#xD;
             relevant by the investigator.&#xD;
&#xD;
        Inclusion criteria for patients with mild cognitive impairment:&#xD;
&#xD;
          -  Men and women aged over 50 years&#xD;
&#xD;
          -  Normal ophthalmic findings, ametropia &lt; 6 Dpt.&#xD;
&#xD;
          -  Diagnosis of probable mild cognitive impairment (MCI) defined as:&#xD;
&#xD;
               1. memory complaint, corroborated by an informant&#xD;
&#xD;
               2. abnormal memory function, documented by delayed recall of one paragraph from the&#xD;
                  Logical Memory II subtest of the Wechsler Memory Scale-Revised (cutoff scores: ≤8&#xD;
                  for ≥16 years of education; ≤4 for 8 to 15 years of education; and ≤2 for 0 to 7&#xD;
                  years of education [the maximum number of paragraph items possible to correctly&#xD;
                  recall is 25])&#xD;
&#xD;
               3. normal general cognitive function, as determined by a clinician's judgment based&#xD;
                  on a structured interview with the patient and an informant (Clinical Dementia&#xD;
                  Rating [CDR]) and a Mini-Mental State Examination (MMSE) score greater than 26&#xD;
&#xD;
               4. no or minimal impairment in activities of daily living (ADLs), as determined by a&#xD;
                  clinical interview with the patient and informant&#xD;
&#xD;
               5. not sufficiently impaired, cognitively and functionally, to meet the NINCDS/ADRDA&#xD;
                  criteria, as judged by an experienced AD research clinician&#xD;
&#xD;
          -  Hachinski Ischemia Scale is used to try and distinguish MCI from multi-infarct&#xD;
             dementia. A score of ≤ 4 suggests MCI Informed consent capability&#xD;
&#xD;
          -  Adequate visual and auditory acuity to allow neuropsychological testing and&#xD;
             participation in the ocular blood flow measurements&#xD;
&#xD;
          -  A potential participant has to be on stable doses of all medications he/she is taking&#xD;
             because of consisting illnesses according to medical for at least 30 days prior&#xD;
             inclusion, if considered relevant by the investigator.&#xD;
&#xD;
        Exclusion Criteria for patients:&#xD;
&#xD;
          -  Presence or history of a severe medical condition other than cognitive impairment as&#xD;
             judged by the clinical investigator&#xD;
&#xD;
          -  Untreated Arterial hypertension&#xD;
&#xD;
          -  History or family history of epilepsy&#xD;
&#xD;
          -  Presence of any abnormalities preventing reliable measurements in the study eye as&#xD;
             judged by the investigator&#xD;
&#xD;
          -  Best corrected visual acuity &lt; 0.5 Snellen&#xD;
&#xD;
          -  Ametropia greater than 6 Dpt&#xD;
&#xD;
          -  pregnancy or planned pregnancy&#xD;
&#xD;
          -  Major psychiatric disorder (e.g. schizophrenia), if considered relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Significant neurological disease other than AD or MCI, if considered relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Alcoholism or substance abuse&#xD;
&#xD;
        Exclusion criteria for healthy volunteers:&#xD;
&#xD;
          -  Presence or history of a severe medical condition as judged by the clinical&#xD;
             investigator&#xD;
&#xD;
          -  Untreated Arterial hypertension&#xD;
&#xD;
          -  History or family history of epilepsy&#xD;
&#xD;
          -  Presence of any abnormalities preventing reliable measurements in the study eye as&#xD;
             judged by the investigator&#xD;
&#xD;
          -  Family history of AD&#xD;
&#xD;
          -  Best corrected visual acuity &lt; 0.5 Snellen&#xD;
&#xD;
          -  Ametropia 6 Dpt&#xD;
&#xD;
          -  Pregnancy or planned pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Garhöfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerhard Garhöfer, MD</last_name>
    <phone>0043140400</phone>
    <phone_ext>29810</phone_ext>
    <email>gerhard.garhoefer@medunwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Garhöfer, MD</last_name>
      <phone>+43 (1) 40400</phone>
      <phone_ext>29810</phone_ext>
      <email>gerhard.garhoefer@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Gerhard Garhöfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>April 6, 2022</last_update_submitted>
  <last_update_submitted_qc>April 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerhard Garhofer</investigator_full_name>
    <investigator_title>Assoc. Prof. PD Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

